Predictive and prognostic factors in small cell lung cancer: Current status

Lung Cancer

Volumn 28, Issue 3, 2000, Pages 173-185

  Yip, Desmond ^a   Harper, Peter G ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Predictive factors; Prognostic factors; Small cell lung cancer; Survival; Treatment related mortality

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MACROLIDE; METHOTREXATE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VINCRISTINE;

ANTIBIOTIC PROPHYLAXIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HIGH RISK PATIENT; HUMAN; LUNG SMALL CELL CANCER; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME;

EID: 0034059515     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00105-7     Document Type: Article

References (80)

1. Hansen H., Pappot H. Primary malignant tumours of the lung and pleura. Cavalli F., Hansen H., Kaye S. Textbook of Medical Oncology. 1997;139-157 Martin Dunitz, London.
2. Aisner J. Extensive-disease small cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol. 12:1996;658-665.
3. Souhami R., Law K. Longevity in small cell lung cancer. Br. J. Cancer. 61:1990;584-589.
4. Gasparini G., Pozza F., Harris A.L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 85:1993;1206-1219.
5. Ihde D.C., Makuch R.W., Carney D.N. et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am. Rev. Respir. Dis. 123:1981;500-507.
6. Shepherd F.A., Ginsberg R.J., Haddad R. et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. J. Clin. Oncol. 11:1993;1592-1597.
7. Wurschmidt F., Bunemann H., Heilmann H.P. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;77-82.
8. Maurer L.H., Pajak T.F. Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. Cancer Treat. Rep. 65:1981;767-774.
9. Osterlind K., Andersen P.K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 46:1986;4189-4194.
10. Anonymous Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br. J. Cancer. 59:1989;584-590. Report to the Medical Research Council by its Lung Cancer Working Party.
11. Poplin E., Thompson B., Whitacre M. et al. Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat. Rep. 71:1987;291-296.
12. Cerny T., Blair V., Anderson H. et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int. J. Cancer. 39:1987;146-149.
13. Allan S.G., Stewart M.E., Love S. et al. Prognosis at presentation of small cell carcinoma of the lung. Eur. J. Cancer. 26:1990;703-705.
14. Chute J.P., Venzon D.J., Hankins L. et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo. Clin. Proc. 72:1997;901-912.
15. Kawahara M., Fukuoka M., Saijo N. et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn. J. Clin. Oncol. 27:1997;158-165.
16. Findlay M.P., Griffin A.M., Raghavan D. et al. Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur. J. Cancer. 27:1991;1597-1601.
17. Yip D., Harper P.G. Cancer in the elderly: gathering the evidence. Med. J. Aust. 170:1999;577-578.
18. Albain K.S., Crowley J.J., LeBlanc M. et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J. Clin. Oncol. 8:1990;1563-1574.
19. Kelly P., O'Brien A., Daly P. et al. Small cell carcinoma in elderly patients: the case for chemotherapy. Age Ageing. 20:1991;19-22.
20. Goss G., Logan D., Maroun J. et al. Chemotherapy in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 11:1992;290. Abstract.
21. Paccagnella A., Favaretto A., Cipriani A. et al. Treatment of small cell lung cancer (SCLC) in elderly patients. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 15:1996;A1164. Meeting abstract.
22. Shepherd F.A., Amdemichael E., Evans W.K. et al. Treatment of small cell lung cancer in the elderly. J. Am. Geriatr. Soc. 42:1994;64-70.
23. Siu L.L., Shepherd F.A., Murray N. et al. Influence of age on the treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 14:1996;821-828.
24. Quon H., Shepherd F.A., Payne D.G. et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;39-45.
25. Johnson D.H. Small cell lung cancer in the elderly patient. Semin. Oncol. 24:1997;484-491.
26. Osterlind K., Hansen H.H., Hansen M. et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J. Clin. Oncol. 4:1986;1307-1313.
27. Spiegelman D., Maurer L.H., Ware J.H. et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1521 patients. J. Clin. Oncol. 7:1989;344-354.
28. Wolf M., Holle R., Hans K. et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br. J. Cancer. 63:1991;986-992.
29. Sagman U., Maki E., Evans W.K. et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J. Clin. Oncol. 9:1991;1639-1649.
30. Shepherd F.A., Laskey J., Evans W.K. et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J. Clin. Oncol. 10:1992;21-27.
31. Delisle L., Boyer M.J., Warr D. et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch. Intern. Med. 153:1993;746-752.
32. Dimopoulos M.A., Fernandez J.F., Samaan N.A. et al. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer. 69:1992;66-71.
33. Maddison P., Newsom-Davis J., Mills K.R. et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 353:1999;117-118. letter.
34. Cohen M.H., Makuch R., Johnston-Early A. et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat. Rep. 65:1981;187-195.
35. Souhami R.L., Bradbury I., Geddes D.M. et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 45:1985;2878-2882.
36. Souhami R.L., Earl H.M., Ash C.M. et al. Prognostic factors in patients with small-cell lung cancer: preliminary results from a large randomised study. Antibiot. Chemother. 41:1988;77-82.
37. Rawson N.S., Peto J. An overview of prognostic factors in small cell lung cancer. Br. J. Cancer. 61:1990;597-604. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Published erratum appears in Br J Cancer 1990;62(3):550.
38. Sagman U., Feld R., Evans W.K. et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J. Clin. Oncol. 9:1991;954-961.
39. Carney D.N., Matthews M.J., Ihde D.C. et al. Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival. J. Natl. Cancer Inst. 65:1980;1225-1230.
40. Fushimi H., Kukui M., Morino H. et al. Detection of large cell component in small cell lung carcinoma by combined cytologic and histologic examinations and its clinical implication. Cancer. 70:1992;599-605.
41. Hirsch F.R., Osterlind K., Hansen H.H. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer. 52:1983;2144-2150.
42. Radice P.A., Matthews M.J., Ihde D.C. et al. The clinical behavior of 'mixed' small cell/large cell bronchogenic carcinoma compared to 'pure' small cell subtypes. Cancer. 50:1982;2894-2902.
43. Sehested M., Hirsch F.R., Osterlind K. et al. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and post-treatment specimens in 104 patients. Cancer. 57:1986;804-807.
44. Bobrow L.G., Hirsch F.R., Hay F.G. et al. An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer. Br. J. Cancer. 66:1992;547-551.
45. Viren M.M., Ojala A.T., Kataja V.V. et al. Flow cytometric analysis of tumor DNA profile related to response to treatment and survival in small-cell lung cancer. Med. Oncol. 14:1997;35-38.
46. Kimura T., Sato T., Onodera K. Clinical significance of DNA measurements in small cell lung cancer. Cancer. 72:1993;3216-3222.
47. Jorgensen L.G., Osterlind K., Genolla J. et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br. J. Cancer. 74:1996;463-467. published erratum appears in Br J Cancer 1996;74(12):2043.
48. Fizazi K., Cojean I., Pignon J.P. et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer. 82:1998;1049-1055.
49. Darnell R.B., DeAngelis L.M. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 341:1993;21-22.
50. Graus F., Dalmou J., Rene R. et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J. Clin. Oncol. 15:1997;2866-2872.
51. Hirsch F.R., Hansen H.H., Hansen M. et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J. Clin. Oncol. 5:1987;585-591.
52. Morittu L., Earl H.M., Souhami R.L. et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br. J. Cancer. 59:1989;801-804.
53. Radford J.A., Ryder W.D., Dodwell D. et al. Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur. J. Cancer. 29A:1992;81-86.
54. Stephens R.J., Girling D.J., Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer. 11:1994;259-274.
55. James L.E., Gower N.H., Rudd R.M. et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br. J. Cancer. 73:1996;1563-1568.
56. Engels E.A., Lau J., Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J. Clin. Oncol. 16:1998;1179-1187.
57. Cruciani M., Rampazzo R., Malena M. et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin. Infect. Dis. 23:1996;795-805.
58. Messori A., Trippoli S., Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J. Clin. Pharm. Ther. 21:1996;57-63.
59. Klasa R.J., Murray N., Coldman A.J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. 9:1991;499-508.
60. Randomised trial of four-drug vs. less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br. J. Cancer. 73:1996;406-413.
61. Arriagada R., Le Chavalier T., Pignon J.P. et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. New Engl. J. Med. 329:1993;1848-1852.
62. Souhami R.L., Spiro S.G., Rudd R.M. et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J. Natl. Cancer Inst. 89:1997;577-580.
63. Murray N., Livingston R., Shepherd F. et al. Randomized study of CODE versus alternating CAV/PE for extensive-stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J. Clin. Oncol. 17:1999;2300-2308.
64. Sculier J.P., Paesmans M., Bureau G. et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J. Clin. Oncol. 11:1993;1858-1865.
65. Souhami R.L., Rudd R., Ruiz de Elvira M.C. et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J. Clin. Oncol. 12:1994;1806-1813.
66. Pujol J.L., Douillard J.Y., Riviere A. et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J. Clin. Oncol. 15:1997;2082-2089.
67. Steward W.P., von Pawel J., Gatzemeier U. et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J. Clin. Oncol. 16:1998;642-650.
68. Thatcher N., Sambrook R., Stephens R. et al. Dose intensification with G-CSF improves survival in small-cell lung cancer: results of a randomized trial. Proc. Am. Soc. Clin. Oncol. 17:1998;456a.
69. Humblet Y., Symann M., Bosly A. et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J. Clin. Oncol. 5:1987;1864-1873.
70. Leyvraz S., Perey L., Rosti G. et al. Multiple courses of high dose ifophamide, carboplatin and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for blood and marrow transplantation. J. Clin. Oncol. 17:1999;3531-3539.
71. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J. Clin. Oncol. 10:1992;890-895.
72. Pignon J.P., Arriagada R., Ihde D.C. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl. J. Med. 327:1992;1618-1624.
73. Albain K.S., Crowley J.J., Livingston R.B. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest. 99:1991;1425-1432.
74. Jacoulet P., Depierre A., Moro D. et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise. Ann. Oncol. 8:1997;1009-1014.
75. Auperin A., Arriagada R., Pignon J. et al. Prophylactic cranial irradiation for patients with small cell cancer in complete remission. New Engl. J. Med. 341:1999;476-484.
76. Lassen U.N., Hirsch F.R., Osterlind K. et al. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer. 20:1998;151-160.
77. Feinstein A.R., Sosin D.M., Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New Engl. J. Med. 312:1985;1604-1608.
78. Hirsch F.R., Osterlind K., Jensen L.I. et al. The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. Ann. Oncol. 3:1992;469-474.
79. Sambook R., Girling D. A national survey of chemotherapy (CT) in small cell lung cancer (SCLC). Br. J. Cancer. 80(Suppl 2):1999;14.
80. Collichio F.A., Woolf P.D., Brower M. Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer. 73:1994;1361-1367.